Lipoprotein (a)-We Know So Much Yet Still Have Much to Learn ….

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis.Drugs · 2017
   Pooled it
2. L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study.Lipids · 2017 · on this map
   Trial
3. The Impact of Elevated Lipoprotein (a) Levels on Postoperative Outcomes in Carotid Endarterectomy: A Systematic Review.Journal of clinical medicine · 2025
   Review
4. 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders.Archives of medical science : AMS · 2024
   Article
5. Altered Functionality of Lipoprotein(a) Impacts on Angiogenesis in Diabetic Retinopathy.Investigative ophthalmology & visual science · 2023
   Article
6. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.Archives of medical science : AMS · 2021
   Article
7. Glycosphingolipid-associated β-1,4 galactosyltransferase is elevated in patients with systemic lupus erythematosus.Lupus science & medicine · 2020
   Observational
8. 2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders.Archives of medical science : AMS · 2020
   Article
9. Dietary natural products as emerging lipoprotein(a)-lowering agents.Journal of cellular physiology · 2019
   Review
10. Calcific aortic valve stenosis: hard disease in the heart: A biomolecular approach towards diagnosis and treatment.European heart journal · 2018
    Review
11. Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity.Scientific reports · 2017
    Article
12. Coronary Atherosclerotic Vulnerable Plaque: Current Perspectives.Journal of the American Heart Association · 2017
    Review
13. PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.Archives of medical science : AMS · 2017
    Article
14. Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.Journal of thoracic disease · 2017
    Article
15. Risk burdens of modifiable risk factors incorporating lipoprotein (a) and low serum albumin concentrations for first incident acute myocardial infarction.Scientific reports · 2016
    Article
16. Poststatin Lipid Therapeutics: A Review.Methodist DeBakey cardiovascular journal
    Review

Corrections and comments

• Comment on
  Lipoprotein(a) Interactions With Low-Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS).2016

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as